Young Chinese consumers, including a growing number of men, are splurging on aesthetic medical treatments for physical, emotional and social wellness, according to the CEO of Fosun Pharma‑backed Sisram Medical and its subsidiary Alma, who says Asia’s relatively low penetration offers greater growth potential than North America.
“It is a global trend that younger generations, including those [in mainland China] and Hong Kong, are turning to energy-based aesthetic treatments such as lasers as a preventive measure – keeping their collagen healthy before there’s anything to fix,” said Lior Dayan in an interview with the Post on Monday. “The demand in Asia is very high and it will increase.”
The Asia-Pacific region, which accounted for about 40 per cent of Sisram’s total revenue of US$165.5 million in the first half of the year, was the only market to record revenue growth, compared with declines in North America, Europe, the Middle East, Africa and Latin America, according to its filing with the Hong Kong stock exchange.
